Most discriminative miRNAs (FDR <0.1) for patients with and without cGVHD
| miRNA . | Fold difference . | Log fold difference . | P value . | FDR . | Number of patients . |
|---|---|---|---|---|---|
| miR-148a-3p | 1.437328 | 0.523389 | .000201 | 0.0264 | 79 |
| miR-365a-3p | 1.863069 | 0.897681 | .000303 | 0.0264 | 76 |
| miR-122-5p | 1.764591 | 0.819334 | .00034 | 0.0264 | 79 |
| miR-378a-3p | 1.34327 | 0.425749 | .000617 | 0.0359 | 79 |
| miR-192-5p | 1.464128 | 0.550042 | .000851 | 0.0396 | 79 |
| miR-194-5p | 1.416809 | 0.502645 | .001335 | 0.0519 | 79 |
| miR-885-5p | 1.810141 | 0.856102 | .001744 | 0.0581 | 77 |
| miR-27b-3p | 1.359085 | 0.442636 | .002402 | 0.0700 | 79 |
| miR-885-3p | 1.817219 | 0.861732 | .003039 | 0.0787 | 79 |
| miR-139-5p | 1.460209 | 0.546175 | .003877 | 0.0903 | 76 |
| miRNA . | Fold difference . | Log fold difference . | P value . | FDR . | Number of patients . |
|---|---|---|---|---|---|
| miR-148a-3p | 1.437328 | 0.523389 | .000201 | 0.0264 | 79 |
| miR-365a-3p | 1.863069 | 0.897681 | .000303 | 0.0264 | 76 |
| miR-122-5p | 1.764591 | 0.819334 | .00034 | 0.0264 | 79 |
| miR-378a-3p | 1.34327 | 0.425749 | .000617 | 0.0359 | 79 |
| miR-192-5p | 1.464128 | 0.550042 | .000851 | 0.0396 | 79 |
| miR-194-5p | 1.416809 | 0.502645 | .001335 | 0.0519 | 79 |
| miR-885-5p | 1.810141 | 0.856102 | .001744 | 0.0581 | 77 |
| miR-27b-3p | 1.359085 | 0.442636 | .002402 | 0.0700 | 79 |
| miR-885-3p | 1.817219 | 0.861732 | .003039 | 0.0787 | 79 |
| miR-139-5p | 1.460209 | 0.546175 | .003877 | 0.0903 | 76 |
The table shows the most discriminative miRNAs that separated patients with cGVHD and patients without cGVHD at 1-year control after allo-HSCT. Fold change and P values are defined by multifactorial statistical tests based on a negative binomial generalized linear model. FDR is calculated based on the 233 miRNAs, with <10 undetectable miRNAs among the 79 included patients. The number of patients that had detectable serum levels of each miRNA is shown (far right column).